La cadena de opciones muestra datos clave de las opciones de acciones de Star Equity Hldgs a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Star Equity Hldgs..

Star Equity Hldgs (NASDAQ:STRRP) Bolsa, Cadena de Opciones

Star Equity Hldgs

Star Equity Holdings Inc is a multi-industry diversified holding company. It operates in two segments: Building Solutions segment, through KBS, EBGL and TT, it services residential and commercial construction projects by manufacturing modular housing units, structural wall panels, permanent wood foundation systems, other engineered wood products, and supply general contractors with building materials; and Investments segment, which holds corporate-owned real estate, currently includes one manufacturing facility and the equipment for another manufacturing facility in Maine that it leases back to KBS and its manufacturing facility in Wisconsin that it leases back to TT. The company derives maximum revenue from Building Solutions Segment.

D. Boral Capital analyst Jason Kolbert maintains OS Therapies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OSTX#AMEX">OSTX</a>) with a Buy and maintains $20 price target.

News

Price Target

Analyst Ratings

OSTX

D. Boral Capital Maintains Buy on OS Therapies, Maintains $20 Price Target

JMP Securities analyst Trevor Cranston downgrades Two Harbors Inv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWO#NYSE">TWO</a>) from Market Outperform to Market Perform.

Downgrades

JMP Securities Downgrades Two Harbors Inv to Market Perform

WIIM

MIRA

MIRA Pharmaceuticals shares are trading higher after the company reported clinical data for Mira-55. Additionally, the company announced it is making advancements regarding its SKNY acquisition.

New benchmark confirms LENSai's ability to accurately predict binding on 17 previously unseen antibody-antigen complexes, achieving near-crystallography precision without prior training data.
ImmunoPrecise Antibodies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPA#NASDAQ">IPA</a>) ("IPA" or the "Company"), an AI-powered biotherapeutics company, today announced a new validation study supporting the generalizability of its proprietary epitope mapping platform, LENSai, powered by IPA's patented HYFT&#xAE; technology. The newly released benchmark shows that the platform consistently delivers high predictive performance, even on complexes not used during training.

Biotech

General

ImmunoPrecise's LENSai Achieves Ability To Accurately Predict Binding On 17 Previously Unseen Antibody-Antigen Complexes, Achieving Near-Crystallography Precision Without Prior Training Data

Inovio Pharmaceuticals shares are trading lower after the company announced a $25 million public offering.

Canaccord Genuity analyst Joseph Vafi maintains HIVE Digital Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIVE#NASDAQ">HIVE</a>) with a Buy and maintains $9 price target.

HIVE

Canaccord Genuity Maintains Buy on HIVE Digital Technologies, Maintains $9 Price Target

Jones Trading analyst Justin Walsh downgrades Theratechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THTX#NASDAQ">THTX</a>) from Buy to Hold.

THTX

Jones Trading Downgrades Theratechnologies to Hold

AEBI

Aebi Schmidt shares are trading higher after making its Nasdaq debut following its merger with the Shyft Group.

<ul>
<li>High-Volume Hemodiafiltration is used for the first time in seven out of 10 CCINSHAE centers in Mexico</li>
<li>In Mexico, 240 CCINSHAE patients are now being treated; more than 410 regular patients also treated</li>
<li>Fresenius Medical Care is committed to expanding HighVolumeHDF therapy to all markets where it is not already present, including the United States</li>
</ul>
BAD HOMBURG, Germany, July 3, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, will extend High-Volume Hemodiafiltration&nbsp;(HighVolumeHDF)&nbsp;access for patients in seven out of 10 centers in Mexico, by partnering with the country's Coordination of National Institutes of Health and Specialty Hospitals (CCINSHAE) to develop a pilot program that provides low-income patients without medical coverage in Mexico with access to hemodialysis therapies. &nbsp;
Fresenius Medical Care Mexico and CCINSHAE signed a two-year contract to enable the installation of the Fresenius Medical Care 5008S CorDiax technology in participating renal treatment centers in CCINCSHAE Centers in Mexico City (CDMX) and its metropolitan area, for a total of 150 systems in all.

FME To Extend HighVolumeHDF Access For Patients In Seven Out Of 10 Centers In Mexico, By Partnering With CCINSHAE To Develop Pilot Program Providing Low-Income Patients Without Medical Coverage In Mexico With Access To Hemodialysis Therapies

Telsey Advisory Group analyst Joseph Feldman maintains Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) with a Outperform and maintains $1100 price target.

COST

Telsey Advisory Group Maintains Outperform on Costco Wholesale, Maintains $1100 Price Target

RedCloud Holdings plc ("RCT") ("RedCloud" or the "Company"), today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors to purchase its ordinary shares, and accompanying warrants that is expected to result in approximately $13.5 million in gross &nbsp;proceeds&nbsp; &nbsp;before deducting placement agent fees and other private placement expenses.
The private placement includes an investment of $7.5M from the Company's largest current shareholder and one of its directors.
At the closing, the Company will issue to the investors an aggregate of 9,000,000 ordinary shares, along with accompanying warrants to purchase an aggregate of 18,000,000 ordinary shares, at a combined purchase price of $1.50 per ordinary share and accompanying warrants. The accompanying warrants have an exercise price of $1.50 per ordinary share and will become exercisable&nbsp;immediately. The Warrants will expire five years from the date of issuance. The private placement is expected to close on or around July 7, 2025, subject to the satisfaction of customary closing conditions.
Roth Capital Partners is acting as the exclusive placement agent for the private placement and Clear Street is acting as financial advisor.

Offerings

RedCloud Holdings Announces $13.5M Private Placement Of 9M Shares And 18M Warrants At A Combined Price Of $1.50

E2open Parent Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETWO#NASDAQ">ETWO</a>) will release earnings results for the first quarter, after the <a href="https://www.benzinga.com/quote/ETWO/earnings">closing bell on Thursday, July 10.</a>
Analysts expect the Addison, Texas-based company to report quarterly earnings at 4 cents per share, compared to 4 cents per share in the year-ago period. E2open projects to report quarterly revenue of $148.92 million, compared to $151.16 million a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On May 25, E2open agreed to be acquired by WiseTech Global for $3.30/share in all-cash deal following strategic review.
E2open shares gained 0.6% to close at $3.25 on Wednesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/etwo/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Goldman Sachs analyst Adam Hotchkiss maintained a Sell rating and cut the price target from $2.6 to $2.3 on March 28, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Loop Capital analyst Mark Schappel maintained a Hold rating and slashed the price target from $4 to $3 on Dec. 23, 2024. This analyst has an accuracy rate of 66%.</li>
</ul>
Considering buying ETWO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/etwo/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="630" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03035121/image-34-1024x630.png" alt="" class="wp-image-971548" style="width:603px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03035121/image-34-1024x630.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03035121/image-34-300x185.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03035121/image-34-768x473.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03035121/image-34.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next:<a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46218519/jim-cramer-gives-utilities-stock-a-week-says-doge-not-done-clobbering-booz-allen"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46218519/jim-cramer-gives-utilities-stock-a-week-says-doge-not-done-clobbering-booz-allen">Jim Cramer Gives Utilities Stock &#8216;A Week,&#8217; Says DOGE &#8216;Not Done Clobbering&#8217; Booz Allen</a> </li>
</ul>
Photo via Shutterstock

Earnings

Markets

Trading Ideas

ETWO

Top Wall Street Forecasters Revamp E2open Expectations Ahead Of Q1 Earnings

U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Thursday.
Shares of Franklin Covey Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) fell sharply in today's pre-market trading after the reported downbeat results for the third quarter and lowered its FY2025 sales guidance <a href="https://www.benzinga.com/quote/FC/earnings">after the closing bell on Wednesday</a>.
The company posted a quarterly loss of 11 cents per share, which missed the analyst consensus estimate of a loss of 4 cents per share. The company reported quarterly sales of $67.121 million, which missed the analyst consensus estimate of $67.491 million.
Franklin Covey shares dipped 10.1% to $21.72 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Noah Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOAH#NYSE">NOAH</a>) shares dipped 7.3% to $11.69 in pre-market trading.</li>
<li>Scage Future American Depositary Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCAG#NASDAQ">SCAG</a>) fell 6.3% to $5.20 in pre-market trading after jumping over 34% on Wednesday.</li>
<li>Borr Drilling Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BORR#NYSE">BORR</a>) declined 4.7% to $2.01 in pre-market trading after the company announced a $100 million offering of approximately 50 million shares.</li>
<li>Lithium Argentina AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAR#NYSE">LAR</a>) fell 4.7% to $2.23 in pre-market trading after gaining 11% on Wednesday.</li>
<li>Bitmine Immersion Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#NYSE">BMNR</a>) fell 4.6% to $55.81 in pre-market trading after gaining 27% on Wednesday.</li>
<li>Northern Dynasty Minerals Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NAK#NYSE">NAK</a>) declined 4.2% to $1.3600 in pre-market trading after falling 4% on Wednesday.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46218519/jim-cramer-gives-utilities-stock-a-week-says-doge-not-done-clobbering-booz-allen">Jim Cramer Gives Utilities Stock &#8216;A Week,&#8217; Says DOGE &#8216;Not Done Clobbering&#8217; Booz Allen</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Movers

BMNR

BORR

NOAH

SCAG

Franklin Covey, Borr Drilling And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Wolfe Research analyst Bill Carcache upgrades Huntington Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBAN#NASDAQ">HBAN</a>) from Peer Perform to Outperform.

Upgrades

HBAN

Wolfe Research Upgrades Huntington Bancshares to Outperform

INVZ

Innoviz Regains Compliance with Nasdaq

Wolfe Research analyst Bill Carcache downgrades PNC Financial Services Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNC#NYSE">PNC</a>) from Outperform to Peer Perform.

Wolfe Research Downgrades PNC Financial Services Gr to Peer Perform

Corporate Update on SKNY Merger
MIRA also announced continued progress on its previously disclosed acquisition of SKNY Pharmaceuticals, the developer of SKNY-1, a novel investigational therapy targeting both obesity and nicotine addiction. In recent studies, SKNY-1 demonstrated a 30% reduction in body weight without muscle loss, along with a reversal of nicotine cravings-highlighting its potential as a differentiated treatment in two major markets. The U.S. Securities and Exchange Commission (SEC) has completed its review of the merger proxy with no comments, allowing MIRA to proceed with shareholder approval and the final steps toward completing the transaction.
"We are pleased to report that the SEC had no comments on our merger filing, which reflects the quality of our regulatory and business preparation," said Aminov. "This milestone allows us to advance toward shareholder approval with clarity and confidence as we prepare for the next phase of growth."

MIRA Pharma Advances SKNY Acquisition As SEC Clears Merger Proxy; SKNY-1 Shows 30% Weight Loss And Reverses Nicotine Cravings

Anthony Scaramucci, founder and managing partner of SkyBridge Capital, believes the recent surge in public companies adopting <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46201788/public-companies-are-quietly-building-massive-bitcoin-treasuries-faster-than-etfs-can-keep-up">crypto treasury strategies</a> is unlikely to last.
What Happened: In an interview with Blooomberg, Scaramucci <a href="https://www.bloomberg.com/news/articles/2025-07-02/scaramucci-says-crypto-treasury-company-trend-will-fade-away?embedded-checkout=true">said</a> the current wave of firms mimicking Michael Saylor's Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) treasury model is likely to fade over time.
"We're seeing this replication of the crypto treasury company idea right now," Scaramucci said. "But eventually, that will fade."
According to Scaramucci, investors may soon realize it makes little sense to pay a premium for shares in companies that primarily hold Bitcoin or other crypto assets, assets that investors could purchase directly themselves. 
"Why pay the middleman?" he asked.
Over the past year, several public companies have aggressively pursued crypto treasury strategies, inspired by Saylor's playbook at Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) (formerly MicroStrategy). 
The latest is BitMine Immersion Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#AMEX">BMNR</a>), a Bitcoin mining firm that announced a $250 million private raise this week to build an Ethereum treasury.
BitMine also appointed Thomas Lee, founder of Fundstrat and a frequent CNBC contributor, as its board chairman.
Many of these companies have sought to differentiate themselves by enlisting high-profile advisors. 
Examples include Eric Trump, who serves on the board of Metaplanet (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MTPLF#OTC">MTPLF</a>), often referred to as Japan's answer to Strategy and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) co-founder Joe Lubin, who is chairman at Sharplink Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>), a former betting company now focused on Ethereum treasury management.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46228386/inside-the-trump-familys-620-million-crypto-empire">Inside The Trump Family&#8217;s $620 Million Crypto Empire</a>
"Saylor's position is unique because Strategy is now offering multiple products," Scaramucci said. "I'm not criticizing the others—I'm bullish on Bitcoin—but investors need to carefully examine the hidden costs within each of these crypto treasury firms."
SkyBridge's crypto-focused ETF, the First Trust SkyBridge Crypto Industry and Digital Economy ETF, lists Strategy as its largest holding. 
Saylor also wrote the foreword to Scaramucci's recently published Bitcoin book.
Why It Matters: While Wall Street has launched an increasing number of crypto ETFs and diversified investment products, some of which compete with crypto treasury firms like Strategy, Strategy remains one of the year's top-performing crypto-related stocks.
Strategy has funded its extensive Bitcoin purchases through a complex mix of stock and debt offerings, including convertible notes and, most recently, preferred shares.
The crypto treasury model has also faced criticism. Short-seller Jim Chanos recently labeled Saylor's approach as &#8220;financial gibberish,&#8221; arguing that investors would be better off buying Bitcoin directly rather than paying premiums for shares in companies like Strategy. 
Saylor dismissed Chanos's concerns, defending the premium that Strategy's shares command over its Bitcoin holdings.
Scaramucci raised a similar question. 
"If you give a company $10 and they put $8 into Bitcoin, will they make money? Probably. But you might have done better just buying $10 worth of Bitcoin yourself. That's the real issue," he said.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46227149/every-new-trillion-of-debt-in-trumps-big-beautiful-bill-is-free-adertising-for-bitcoin-expert-states">Every New Trillion Of Debt In Trump&#8217;s &#8216;Big Beautiful Bill&#8217; Is &#8216;Free Adertising For Bitcoin,&#8217; Expert States</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Short Sellers

$BTC

$ETH

MSTR

MTPLF

SBET

Anthony Scaramucci Predicts Bitcoin Treasury Frenzy 'Will Fade'

With Mira-55 and Ketamir-2, MIRA is advancing complementary non-opioid therapies for two of the largest pain markets
MIAMI, FLORIDA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / July 3, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced positive preclinical data demonstrating that Mira-55, the Company's proprietary non-psychotropic marijuana analog, delivered morphine-comparable pain relief in a validated model of inflammatory pain-without causing local inflammation.
Mira-55 is a next-generation analog of marijuana, engineered to selectively activate CB2 cannabinoid receptors, which are associated with anti-inflammatory and analgesic effects. Unlike THC, Mira-55 minimizes activation of CB1 receptors, reducing the risk of euphoria, sedation, and pro-inflammatory side effects.

MIRA Pharma Reports Preclinical Data Showing That Mira-55 Delivered Morphine-Comparable Pain Relief In Validated Model Of Inflammatory Pain-Without Causing Local Inflammation

Telsey Advisory Group analyst Dana Telsey maintains Levi Strauss (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) with a Outperform and maintains $21 price target.

LEVI

Telsey Advisory Group Maintains Outperform on Levi Strauss, Maintains $21 Price Target

Contracts

Press Releases

KBS Builders Wins $2.1 Million Contract For Multifamily Construction Project in Vermont

KBS Builders Awarded $3.2 Million Contract for Multifamily Construction Project in Maine

Dividends

Star Equity Holdings, Inc. Declares Cash Dividend of $0.25 Per Share of 10% Series A Cumulative Perpetual Preferred Stock

Star Equity Holdings Acquires Alliance Drilling Tools

KBS Builders Wins Two Large Commercial Contracts Totaling $5.2 Million for Multifamily Construction Projects in Maine

Star Equity Holdings to Release Fourth Quarter 2024 Financial Results on March 20th

Star Equity Holdings, Inc. Announces 2024 Fourth Quarter and Full Year Financial Results

Star Equity Holdings to Release First Quarter 2025 Financial Results on May 14th

Star Equity Holdings, Inc. Announces 2025 First Quarter Financial Results

STRR

STRRP

Star Equity Holdings, Inc. - Series A Cumulative Perpetual Preferred Stock

Comments

Star Equity Hldgs

Star Equity Hldgs (STRRP) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL